Indivior settles patent litigation with Dr. Reddy's
24th Jun 2022 12:11
(Sharecast News) - Opioid addiction treatment maker Indivior has settled a patent infringement case with generic drug maker Dr. Reddy's Laboratories.
Read moreIndivior maintains guidance after 'strong start' to year
28th Apr 2022 07:53
(Sharecast News) - Pharmaceuticals firm Indivior reported first quarter net revenue of $207m (£165.07m) in an update on Thursday, up 15% year-on-year, as it maintained its guidance for the full year.
Read moreIndivior starts formal shareholder talks over additional US listing
31st Mar 2022 15:26
(Sharecast News) - Opioid addiction treatment maker Indivior said on Thursday that it is beginning formal consultations with shareholders about a potential additional listing of its shares in the US.
Read moreIndivior considers US listing after returning to profit
16th Feb 2022 07:05
(Sharecast News) - Indivior said it was considering a US listing for its shares as the drugs company swung to an annual profit and predicted strong growth for its Sublocade opioid.
Read moreIndivior welcomes results from buprenorphine-fentanyl interaction study
28th Jan 2022 07:55
(Sharecast News) - Pharmaceutical company Indivior hailed the results of a study aimed at assessing the ability of its buprenorphine asset to reduce respiratory depression and apnea associated with the synthetic opioid fentanyl.
Read moreIndivior slumps as Scopia Capital sells 20m shares
10th Nov 2021 08:07
(Sharecast News) - Indivior was under the cosh on Wednesday after US alternative asset management firm Scopia Capital sold 20m shares in the opioid addiction treatment maker in a placing.
Read moreIndivior lifts FY guidance as Q3 profits, revenue jump
28th Oct 2021 12:17
(Sharecast News) - Indivior lifted its full-year guidance on Thursday as it reported a rise in third-quarter revenue and profit.
Read moreSunday share tips: Light Science Technologies, Indivior
24th Oct 2021 17:12
(Sharecast News) - The Financial Mail on Sunday's Midas column told readers to buy shares of Light Science Technologies, pointing out the benefits of the company's technology for health, climate and the UK more economy.
Read moreDirector dealings: Indivior director ups stake
11th Aug 2021 16:08
(Sharecast News) - Indivior revealed on Wednesday that non-executive director Mark Stejbach had acquired 36,000 ordinary shares in the FTSE 250-listed pharmaceuticals business.
Read moreIndivior launches share buyback after strong first half
29th Jul 2021 08:48
(Sharecast News) - Speciality pharmaceuticals company Indivior reiterated its upgraded guidance for 2021 on Thursday, and announced the start of a $100m (£71.71m) share buyback programme, as its first-half net revenue rose to $381m from $303m year-on-year.
Read moreIndivior agrees to reprice and extend maturity of term loan facilities
1st Jul 2021 10:33
(Sharecast News) - Pharmaceutical firm Indivior said on Thursday that it had entered into an amendment to reprice and extend the maturity of $250.0m worth of term loan facilities.
Read moreWednesday broker round-up
30th Jun 2021 13:44
(Sharecast News) - Workspace: RBC Capital Markets upgrades to outperform with a target price of 1,050p.
Read moreIndivior lifts 2021 guidance after better-than-expected H1
30th Jun 2021 07:35
(Sharecast News) - Opioid addiction treatment maker Indivior lifted its 2021 guidance on Wednesday following a better-than-expected business performance through the first half of the year.
Read moreIndivior joins forces with France's Aelis on treatment for cannabis use disorder
8th Jun 2021 12:36
(Sharecast News) - Indivior said on Tuesday that it has teamed up with French biotechnology group Aelis to advance the clinical development of a treatment for cannabis use disorder.
Read moreIndivior teams up with Aelis on treatment for cannabis use disorder
8th Jun 2021 12:36
(Sharecast News) - Indivior said on Tuesday that it has teamed up with French biotechnology group Aelis to advance the clinical development of a treatment for cannabis use disorder.
Read more